Evidence map›Paper›PMID 37615689›Full record

Trial reportDiabetologia2023

Metabolomic insights into maternal and neonatal complications in pregnancies affected by type 1 diabetes.

Claire L Meek, Zoe A Stewart, Denice S Feig, Samuel Furse, Sandra L Neoh, Albert Koulman, Helen R Murphy, CONCEPTT collaborative group

Abstract readClinical Trial
In one paragraph

Trial report in Diabetologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Intrapartum Glycemic Control and Clinical Outcomes.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Claire L MeekWellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. clm70@cam.ac.uk.ORCID 0000-0002-4176-8329
Zoe A StewartDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Denice S FeigMount Sinai Hospital, Sinai Health System, New York, NY, USA.
Samuel FurseCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0003-4267-2051
Sandra L NeohDepartment of Endocrinology, Austin Health, Melbourne, VIC, Australia.ORCID 0000-0001-9387-7079
Albert KoulmanCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0001-9998-051X
Helen R MurphyCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-5489-0614
CONCEPTT collaborative group

Funding

Biotechnology and Biological Sciences Research Council BB/M027252/1Department of Health CDF-2013-06-035
6 · The paper itself

Abstract

aims/hypothesisType 1 diabetes in pregnancy is associated with suboptimal pregnancy outcomes, attributed to maternal hyperglycaemia and offspring hyperinsulinism (quantifiable by cord blood C-peptide). We assessed metabolomic patterns associated with risk factors (maternal hyperglycaemia, diet, BMI, weight gain) and perinatal complications (pre-eclampsia, large for gestational age [LGA], neonatal hypoglycaemia, hyperinsulinism) in the Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy Trial (CONCEPTT).

methodsA total of 174 CONCEPTT participants gave ≥1 non-fasting serum sample for the biorepository at 12 gestational weeks (147 women), 24 weeks (167 women) and 34 weeks (160 women) with cord blood from 93 infants. Results from untargeted metabolite analysis (ultrahigh performance LC-MS) are presented as adjusted logistic/linear regression of maternal and cord blood metabolites, risk factors and perinatal complications using a modified Bonferroni limit of significance for dependent variables.

resultsMaternal continuous glucose monitoring time-above-range (but not BMI or excessive gestational weight gain) was associated with increased triacylglycerols in maternal blood and increased carnitines in cord blood. LGA, adiposity, neonatal hypoglycaemia and offspring hyperinsulinism showed distinct metabolite profiles. LGA was associated with increased carnitines, steroid hormones and lipid metabolites, predominantly in the third trimester. However, neonatal hypoglycaemia and offspring hyperinsulinism were both associated with metabolite changes from the first trimester, featuring triacylglycerols or dietary phenols. Pre-eclampsia was associated with increased abundance of phosphatidylethanolamines, a membrane phospholipid, at 24 weeks. CONCLUSIONS/

interpretationAltered lipid metabolism is a key pathophysiological feature of type 1 diabetes pregnancy. New strategies for optimising maternal diet and insulin dosing from the first trimester are needed to improve pregnancy outcomes in type 1 diabetes.

Indexed as

Diabetes, GestationalDiabetes Mellitus, Type 1HyperglycemiaHyperinsulinismHypoglycemiaPre-EclampsiaBlood GlucoseBlood Glucose Self-MonitoringFemaleHumansInfant, NewbornPregnancyBlood GlucoseCord bloodLGALipidomicsMetabolomicsNeonatal hypoglycaemiaPredictionPre-eclampsiaPregnancyPregnancy complicationsPregnancy in people with diabetesPregnancy outcomeType 1 diabetes

Identifiers

PMID37615689
PMCPMC10542716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.